Skip to content

Study · Observational study · 2017

8 results

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.

Alatorre C, Fernández Landó L, Yu M, Brown K, Montejano L, Juneau P, Mody R, Swindle R

Diabetes, obesity & metabolism16 Mar 2017Cited by 94 (Europe PMC)

PMID28181725 (opens in a new tab)PMCIDPMC5485056 (opens in a new tab)DOI10.1111/dom.12902 (opens in a new tab)PepBankPUB-28181725
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyOther

    In adults with type 2 diabetes newly starting GLP-1 receptor agonists, matched liraglutide users had lower mean adherence than dulaglutide users (0.67 vs 0.71).

    In plain wordsIn adults with type 2 diabetes, people who started liraglutide took it less consistently than matched people who started dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean adherence (proportion of days covered)
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean adherence (PDC)
    0.67 proportion of days covered
    liraglutide cohort

    Source sentences

    Summary
    Mean adherence for the matched cohorts was significantly higher for dulaglutide than for exenatide once weekly (0.72 vs 0.61; P  < .0001) and liraglutide (0.71 vs 0.67; P  < .0001).
    2 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.
  2. 02HumanObservational studyOther

    In adults with type 2 diabetes newly starting GLP-1 receptor agonists, fewer liraglutide users than dulaglutide users reached PDC of 0.80 or more (44.3% vs 53.5%).

    In plain wordsIn adults with type 2 diabetes, fewer people on liraglutide (44.3%) than on dulaglutide (53.5%) took it on most days.

    Peptide
    Liraglutide
    Outcome
    DecreaseProportion of patients with PDC of 0.80 or more
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Patients with PDC >=0.80
    44.3%
    liraglutide cohort

    Source sentences

    Summary
    The percentage of patients achieving PDC ≥ 0.80 was significantly higher for dulaglutide compared with exenatide once weekly (54.2% vs 37.9%; P  < .0001) and liraglutide (53.5% vs 44.3%; P  < .0001).
    2 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.
  3. 03HumanObservational studyOther

    In adults with type 2 diabetes newly starting GLP-1 receptor agonists, liraglutide users had fewer mean days on treatment than dulaglutide users (137.4 vs 146.0).

    In plain wordsIn adults with type 2 diabetes, people on liraglutide stayed on treatment for fewer days (137.4) than people on dulaglutide (146.0).

    Peptide
    Liraglutide
    Outcome
    DecreaseDays on treatment
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean days on treatment
    137.4 days
    liraglutide cohort

    Source sentences

    Summary
    The mean (standard deviation) days on treatment for all matched patients was significantly higher for patients in the dulaglutide cohort compared with those in the exenatide once-weekly (148.4 [55.4] vs 123.6 [61.6]; P  < .0001) and liraglutide cohorts (146.0 [56.9] vs 137.4 [60.1]; P  < .0001).
    2 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.
  4. 04HumanObservational studyOther

    In adults with type 2 diabetes newly starting GLP-1 receptor agonists, a higher proportion of liraglutide users than dulaglutide users discontinued treatment (35.6% vs 28.0%).

    In plain wordsIn adults with type 2 diabetes, more people on liraglutide (35.6%) than on dulaglutide (28.0%) stopped treatment.

    Peptide
    Liraglutide
    Outcome
    IncreaseTreatment discontinuation
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Discontinued treatment
    35.6%
    liraglutide cohort

    Source sentences

    Summary
    A significantly lower proportion of patients on dulaglutide discontinued treatment compared with those on exenatide once weekly (26.2% vs 48.4%; P  < .0001) and those on liraglutide (28.0% vs 35.6%; P  < .0001).
    2 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 05HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In matched type 2 diabetes cohorts, mean adherence was lower with weekly exenatide than dulaglutide.

    In plain wordsIn matched type 2 diabetes cohorts, weekly exenatide was linked to lower adherence than dulaglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMean proportion of days covered
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Whole body

    Measurements

    Mean proportion of days covered
    0.61 proportion
    exenatide once weekly
    Mean proportion of days covered
    0.72 proportion
    dulaglutide

    Source sentences

    Summary
    Mean adherence for the matched cohorts was significantly higher for dulaglutide than for exenatide once weekly (0.72 vs 0.61; P  < .0001)
    3 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.
    Summary · context
    Adherence to and persistence with the index GLP-1RA, and switching and augmentation patterns were assessed during the 6-month post-index period.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 06HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In matched type 2 diabetes cohorts, fewer weekly exenatide recipients achieved the adherence threshold than dulaglutide recipients.

    In plain wordsIn matched type 2 diabetes cohorts, weekly exenatide was linked to fewer patients reaching the adherence threshold than dulaglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProportion of days covered at least 0.80
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Whole body

    Measurements

    Adherence threshold achieved
    37.9%
    exenatide once weekly
    Adherence threshold achieved
    54.2%
    dulaglutide

    Source sentences

    Summary
    The percentage of patients achieving PDC ≥ 0.80 was significantly higher for dulaglutide compared with exenatide once weekly (54.2% vs 37.9%; P  < .0001)
    3 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.
    Summary · context
    Adherence to and persistence with the index GLP-1RA, and switching and augmentation patterns were assessed during the 6-month post-index period.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 07HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In matched type 2 diabetes cohorts, weekly exenatide recipients had fewer days on treatment than dulaglutide recipients.

    In plain wordsIn matched type 2 diabetes cohorts, weekly exenatide was linked to fewer treatment days than dulaglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDays on treatment
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Whole body

    Measurements

    Mean days on treatment
    123.6 days
    exenatide once weekly
    Mean days on treatment
    148.4 days
    dulaglutide

    Source sentences

    Summary
    The mean (standard deviation) days on treatment for all matched patients was significantly higher for patients in the dulaglutide cohort compared with those in the exenatide once-weekly (148.4 [55.4] vs 123.6 [61.6]; P  < .0001)
    3 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.
    Summary · context
    Adherence to and persistence with the index GLP-1RA, and switching and augmentation patterns were assessed during the 6-month post-index period.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 08HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In matched type 2 diabetes cohorts, discontinuation was higher with weekly exenatide than dulaglutide.

    In plain wordsIn matched type 2 diabetes cohorts, weekly exenatide was linked to more treatment discontinuation than dulaglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseTreatment discontinuation
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Whole body

    Measurements

    Treatment discontinuation
    48.4%
    exenatide once weekly
    Treatment discontinuation
    26.2%
    dulaglutide

    Source sentences

    Summary
    A significantly lower proportion of patients on dulaglutide discontinued treatment compared with those on exenatide once weekly (26.2% vs 48.4%; P  < .0001)
    3 context sentences
    Summary · context
    Patients with T2DM newly initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily and liraglutide between November 2014 and April 2015 were hierarchically selected from Truven Health's MarketScan Research Databases.
    Summary · context
    Propensity score matching was used to account for selection bias.
    Summary · context
    Adherence to and persistence with the index GLP-1RA, and switching and augmentation patterns were assessed during the 6-month post-index period.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 8Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.